Val J Lowe1, Fenghai Duan2, Rathan M Subramaniam3, JoRean D Sicks2, Justin Romanoff2, Twyla Bartel4, Jian Q Michael Yu5, Brian Nussenbaum6, Jeremy Richmon7, Charles D Arnold8, David Cognetti9, Brendan C Stack10. 1. 1 Mayo Clinic, Rochester, MN. 2. 2 Brown University School of Public Health, Providence, RI. 3. 3 University of Texas Southwestern Medical Center, Dallas, TX. 4. 4 Global Advanced Imaging, Little Rock, AR. 5. 5 Fox Chase Cancer Center, Philadelphia, PA. 6. 6 Washington University School of Medicine, St. Louis, MO. 7. 7 Massachusetts Eye and Ear Hospital, Boston, MA. 8. 8 University of Oklahoma, Oklahoma City, OK. 9. 9 Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA. 10. 10 University of Arkansas for Medical Sciences, Little Rock, AR.
Abstract
PURPOSE: The objective of this study was to determine the negative predictive value (NPV) of positron emission tomography (PET)/computed tomography (CT) for the clinically N0 neck on the basis of neck dissection. METHODS: Participants with newly diagnosed, first-time, head and neck squamous cell carcinoma (HNSCC) and at least one clinically N0 neck side for which dissection was planned were included. A total of 287 participants were prospectively enrolled from 23 American College of Radiology Imaging Network-qualified institutions. PET/CT was compared with findings at neck dissection. RESULTS: PET/CT scans and pathology findings were available for 270 N0 neck sides from 212 participants. For visual assessment, the NPV specific to the clinical-N0 sides was 0.868 (95% CI, 0.803 to 0.925). For dichotomized maximum standardized uptake value, the NPVs specific to the nodal basins were 0.940 (95% CI, 0.928 to 0.952) and 0.937 (95% CI, 0.925 to 0.949) at prespecified cutoffs of 2.5 and 3.5, respectively. The optimal cutoff maximum standardized uptake value was determined to be 1.8, with an NPV of 0.942 (95% CI, 0.930 to 0.953). The PET/CT-informed surgical treatment plan was changed in 51 of 237 participants (22%) compared with the PET/CT-blinded surgical plan. In 34 participants (14%), this led to planned dissection of additional nodal levels. In 12 participants (5%), this led to fewer planned dissected nodal levels. Negative PET/CT scans in N0 necks was true negative in 87% and false negative in 13%. CONCLUSION: [18F]fluorodeoxyglucose-PET/CT has high NPV for the N0 neck in T2 to T4 HNSCC. The surgical treatment plans on the basis of PET/CT findings may be changed in approximately 22% of this group. These findings suggest that [18F]fluorodeoxyglucose-PET/CT may assist the clinician in deciding on the best therapy for the clinically N0 neck in HNSCC. Well-designed clinical trials should be performed to test the outcome of omitting neck dissection by using PET/CT.
PURPOSE: The objective of this study was to determine the negative predictive value (NPV) of positron emission tomography (PET)/computed tomography (CT) for the clinically N0 neck on the basis of neck dissection. METHODS:Participants with newly diagnosed, first-time, head and neck squamous cell carcinoma (HNSCC) and at least one clinically N0 neck side for which dissection was planned were included. A total of 287 participants were prospectively enrolled from 23 American College of Radiology Imaging Network-qualified institutions. PET/CT was compared with findings at neck dissection. RESULTS: PET/CT scans and pathology findings were available for 270 N0 neck sides from 212 participants. For visual assessment, the NPV specific to the clinical-N0 sides was 0.868 (95% CI, 0.803 to 0.925). For dichotomized maximum standardized uptake value, the NPVs specific to the nodal basins were 0.940 (95% CI, 0.928 to 0.952) and 0.937 (95% CI, 0.925 to 0.949) at prespecified cutoffs of 2.5 and 3.5, respectively. The optimal cutoff maximum standardized uptake value was determined to be 1.8, with an NPV of 0.942 (95% CI, 0.930 to 0.953). The PET/CT-informed surgical treatment plan was changed in 51 of 237 participants (22%) compared with the PET/CT-blinded surgical plan. In 34 participants (14%), this led to planned dissection of additional nodal levels. In 12 participants (5%), this led to fewer planned dissected nodal levels. Negative PET/CT scans in N0 necks was true negative in 87% and false negative in 13%. CONCLUSION:[18F]fluorodeoxyglucose-PET/CT has high NPV for the N0 neck in T2 to T4 HNSCC. The surgical treatment plans on the basis of PET/CT findings may be changed in approximately 22% of this group. These findings suggest that [18F]fluorodeoxyglucose-PET/CT may assist the clinician in deciding on the best therapy for the clinically N0 neck in HNSCC. Well-designed clinical trials should be performed to test the outcome of omitting neck dissection by using PET/CT.
Authors: W L Hicks; D R Kollmorgen; M A Kuriakose; J Orner; V Y Bakamjian; J Winston; T R Loree Journal: Otolaryngol Head Neck Surg Date: 1999-07 Impact factor: 3.497
Authors: Martin Beat Sigg; Hans Steinert; Klaus Grätz; Pia Hugenin; Sandro Stoeckli; Gerold Klaus Eyrich Journal: J Oral Maxillofac Surg Date: 2003-09 Impact factor: 1.895
Authors: C Jillian Tsai; Thomas J Galloway; Danielle N Margalit; Richard L Bakst; Beth M Beadle; Jonathan J Beitler; Steven Chang; Allen Chen; Jay Cooper; Shlomo A Koyfman; John A Ridge; Jared Robbins; Minh Tam Truong; Sue S Yom; Farzan Siddiqui Journal: Head Neck Date: 2020-10-17 Impact factor: 3.821
Authors: Wilko Weichert; Melanie Boxberg; Moritz Jesinghaus; Katja Steiger; Fabian Stögbauer; Bernhard Haller; Andreas Kolk; Ulrich Straßen; Anja Pickhard; Markus Wirth; Miguel Silva; Jan Budczies; Aaron Becker von Rose; Björn Konukiewitz; Peer Kuhn; Konrad Klinghammer; Hendrik Dapper; Stefan Münch; Stephanie E Combs Journal: Br J Cancer Date: 2020-01-15 Impact factor: 7.640
Authors: Axel Sahovaler; John J W Lee; Wei Xu; Susie Su; Ali Hosni; Andrew Bayley; David P Goldstein; John R de Almeida Journal: J Otolaryngol Head Neck Surg Date: 2021-12-23